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This latest HIV/AIDS philanthropy resource tracking report of European funders is based largely 
on responses to surveys, with some supplemental review of annual reports and funders’ websites. 
The European HIV/AIDS Funders Group (EFG) obtained data for a total of 31 funders;1 combined, 
they are believed to represent the substantial majority of private philanthropic HIV/AIDS funding 
from Europe.
Total HIV/AIDS-related philanthropy among the 31 European-based funders reviewed for this report 
amounted to €107 million ($153 million) in 2010. Funding expenditures were slightly lower—by about 
€7 million ($10 million), which corresponds to a 6% decrease—in 2010 compared with 2009, among 
the 30 funders for which EFG has two years of comparable expenditure data (2009 and 2010).
For funders for which five years of comparable data were available (beginning with the year 2006, 
(when expenditures were first reported consistently), the 2010 total expenditures of €71 million 
($102 million) were about €10 million higher than the 2006 total expenditures. In general, it 
appears that European HIV/AIDS philanthropy is remaining relatively stable—neither increasing 
nor decreasing dramatically—amidst ongoing global financial instability as well as a growing 
need for HIV/AIDS services. Looking ahead, funder projections for 2011 indicate that funding 
may increase, with 38% of the funders that answered that question, including five of the top 10 
funders, forecasting an increase from 2010 levels.
Key findings for 2010 include:
1  Several funders that traditionally make substantial grants towards HIV/AIDS were not included in the 2010 analysis for several 
reasons. They include the German Foundation for World Population (DSW), which did not fill out the survey; the Big Lottery 
Fund, which did not make any grants to HIV/AIDS in 2010 due to the development of a new grants programme but has 
resumed grantmaking to HIV/AIDS in 2011; and the Bernard van Leer Foundation, which shifted its focus from HIV/AIDS-specific 
programmes in 2010.
EXECUTIVE SUMMARY
  » HIV/AIDS-related philanthropic funding is increasingly concentrated among a relatively 
small number of European funders. The top 10 funders (ranked by expenditure) 
accounted for 86% of all HIV/AIDS-related expenditures in 2010 (up from 83% in 2009). 
Five of the top 10 funders are organisations that focus specifically on HIV/AIDS.
  » Just over half (16 of 31) of the funders profiled, including six of the top 10 in terms of 
total expenditures, had main offices in the United Kingdom. That country was followed 
by Switzerland (home to four funders of 31), the Netherlands (home to three), and six 
other countries.
  » About €39 million ($57 million), or 36% of all funding, went to support projects within or 
benefiting countries in Western and Central Europe. However, funders allocated a larger 
share—€67 million ($96 million), or 62% of all HIV/AIDS philanthropic expenditures in 
2010—to support projects outside that region. (One percent was unable to be specified.)
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2011 FORECAST 
Funder responses to the EFG survey suggest that their HIV/AIDS-related philanthropy funding levels 
may increase in 2011 in comparison to 2010. Thirty-eight percent of funders that forecast their 2011 
expenditures (10 of 26 that answered this question) anticipated increases in HIV/AIDS-related funding, 
including five of the top 10 funders. Thirty-five percent (9 of 26) of funders expect their HIV/AIDS-
related expenditures to remain about the same, while 12% are unsure about 2011 funding levels. Four 
funders said funding was likely to decrease in 2011, including one of the top 10 funders. 
  » Organisations based in Eastern and Southern Africa received 37% (or €40 million) 
of all funding in 2010, followed by 7% to organisations in Western and Central 
Africa, 5% to organisations based in North America (often for global projects 
benefiting populations outside of that region), 4% to South Asia and the Pacific, 
4% to organisations based in Western and Central Europe for projects benefiting 
populations outside of that region, 3% to East Asia and Southeast Asia, and 1% to 
organisations in each of two other regions (Eastern Europe and Central Asia, and Latin 
America). Two percent was unable to be specified, and the Caribbean and Middle 
East & North Africa regions each received less than 1%.
  » The largest differences in terms of geographical distribution from 2009 to 2010 were 
in Eastern and Southern Africa, which received €8 million more in 2009; and South 
Asia and the Pacific, which received €4 million in 2010, down from €11 million in 
2009. Most of the other regions received about the same in 2009 and 2010.
  » The top five countries where recipients of HIV/AIDS funding from the European 
philanthropic entities in this report were located were the United Kingdom, South 
Africa, France, Malawi, and India. The top five countries were the same as in 2009 
with the exception of the fifth spot, in which India replaced Uganda (which slipped to 
number eight).
  » Regarding the intended use of HIV/AIDS-related giving, the biggest share of 
European HIV/AIDS philanthropic expenditures in 2010 went to research, followed by 
treatment, prevention, and orphans and vulnerable children. Funding for treatment 
experienced the largest decrease from 2009 to 2010, of about €10 million; most other 
categories remained about the same in 2009 and 2010.
  » People living with HIV/AIDS were identified more frequently than any other 
population group as chief beneficiaries of European HIV/AIDS philanthropy. Other 
population groups identified as chief beneficiaries were, in descending order, women, 
orphans and vulnerable children, and youth—unchanged from 2009. No funders 
chose injecting drug users (IDU) as a top target population in 2009 or 2010, even 
though the epidemic in the Eastern Europe and Central Asia region is the fastest 
growing in the world, and is largely driven by injecting drug use.
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The European HIV/AIDS Funders Group (EFG) is a knowledge-based network 
dedicated to strengthening European philanthropy in the field of HIV/AIDS. 
The group aims to mobilise European philanthropic leadership and resources 
to address the global HIV/AIDS pandemic and its health, social and economic 
consequences. In doing so, it also seeks to promote an enabling environment for 
strategic and independent giving in this field as well as fields closely connected 
to HIV/AIDS such as human rights, global health and global development.
EFG was established in June 2002, during the 13th Annual General Assembly of the European 
Foundation Centre (EFC) in Brussels, as a response to the call for sharing knowledge and 
supporting better coordination among European philanthropists already involved or interested in 
becoming involved in HIV/AIDS programming. 
The main objectives of EFG are to identify European foundations engaged in HIV/AIDS work; 
to facilitate the sharing of experiences and perspectives among funders, thereby helping them 
to learn from each other’s successes and failures in this complex funding area; and to discuss 
opportunities for better information exchange and cooperation.
Based on the principal that coordinated, transparent and joint action will increase impact, 
coverage and effectiveness, EFG is increasingly engaged in facilitating cooperation and strategic 
interaction among not only private funders, but also between private funders and their bilateral 
and multilateral funding colleagues. Through this work, EFG aims to assist in spurring the 
development of new initiatives or joint ventures in the HIV/AIDS field. 
The annual resource tracking report European Philanthropic Support to Address HIV/AIDS is a 
joint effort of EFG, its U.S.-based sister organisation Funders Concerned About AIDS (FCAA) 
and UNAIDS to provide resource tracking data on global HIV/AIDS resource flows.2 The report 
on 2010 funding is EFG’s eighth publication that provides data and analysis on HIV/AIDS-
related philanthropic giving by European3 philanthropic institutions, including private, family, 
and community foundations; public charities and trusts; fundraising organisations; lotteries; and 
corporate grantmaking programmes.4 
The information in this report is accurate and current as of September 2011. Resource tracking, 
however, is always a work in progress. Therefore, EFG welcomes any information or input of 
relevance to this report and future work.
2  The data and reporting format for this publication are closely harmonised with that of FCAA’s resource tracking report (available 
at www.fcaaids.org) and follow UNAIDS’ categorisation and terminology where possible.
3   Throughout the report, the term “European” is used to describe the funders profiled. The philanthropic entities featured in 
this year’s report are all based in Western and Central European countries. See Appendix 1 for a more extensive definition of 
philanthropy and the methodology used for this report.
4  Previous EFG resource tracking publications can be found at: www.hivaidsfunders.org/Pages/ResourceTracking.aspx.
ABOUT EFG AND THIS REPORT
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2011 AND THE ROAD AHEAD
This year, which marks three decades since the first diagnosed AIDS case, may prove to be a game-changing 
moment in the history of the AIDS epidemic. Hard-won scientific advances in treatment and prevention offer 
new hope as additional tools to halt HIV transmission and help to overcome some of the most intractable 
epidemiological and social challenges associated with HIV/AIDS. Current financial resources, however, are not 
enough, and have not been enough, at home and abroad, to end HIV/AIDS. 
Resources for HIV/AIDS continue to tragically decrease as research reveals new options and the epidemic is 
stabilising in some areas of the world. During an ongoing period of economic uncertainty, coupled with a growing 
focus on other health and development challenges, serious questions remain as to how to fully utilise new findings 
on HIV prevention and treatment (see table on p7), along with existing tools that have already demonstrated 
success. The emerging consensus is that resources will need to be allocated and used more efficiently, requiring 
greater demonstration of evidence-based and results-oriented programming and shifting to more methodical and 
sustainable long-term approaches. 
Though philanthropic giving represents only a small part of total resources for HIV/AIDS, it has changed the course 
of the epidemic in large part due to funders’ dedicated efforts. Philanthropy possesses an ability to be independent 
and flexible and can address key focus areas such as advocacy and marginalised populations that are not being 
covered by other sources of funding. As more philanthropic funders move away from HIV/AIDS than ever before, 
and resources become more dependent on the few funders at the top, how and where current funding is targeted 
must increasingly exemplify these principles to ensure impact.
The following sections provide a brief overview of current HIV/AIDS scientific progress, available resources, and potential 
funding gaps. As the sector evaluates the road ahead, this information is essential to understanding the future of the 
philanthropic response to HIV/AIDS: where can private funding best innovate, strengthen, and advance the response?
While perspectives differ, one simple truth emerges: we cannot break the 
arc of this epidemic —where ﬁve people were newly infected for every three 
starting treatment in 2010—if we adopt a ‘business as usual’ approach.
– Michel Sidibé, Executive Director, UNAIDS; AIDS at 30: Nations at the Crossroads
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Tool Name of trial/product Date of results Population involved Efficacy
Microbicide CAPRISA 004/TDF gel July 2010 Women 39%
Oral PrEP iPrEx/TDF-FTC daily November 2010
Men who have sex 
with men, transgender 
women
44%
Treatment as 
prevention
HPTN 052/ART for  
HIV-positive people
May 2011
Sero-discordant 
heterosexual couples
96%
In addition to the existing tools for HIV prevention 
such as male circumcision, condoms, harm 
reduction strategies, prevention of vertical 
transmission, and behaviour-change programmes, 
the following interventions look promising as part 
of a combination approach to prevention. 
The “treatment as prevention” concept has 
generated particular interest and excitement5 as it 
appears likely to further break down the persistent 
dichotomy between treatment and prevention 
that has often pitted advocates and policymakers 
against each other in the scramble for resources. 
RECENT SCIENTIFIC ADVANCES
5  AVAC. We CAN End the AIDS Epidemic (statement). June 2011. Available at: www.avac.org/ht/d/sp/i/34301/pid/3430.1
6  Available at: www.hivresourcetracking.org. The Working Group consists of AVAC: Global Advocacy for HIV Prevention, the International AIDS Vaccine 
Initiative (IAVI), the International Partnership for Microbicides (IPM) and UNAIDS.
According to Capitalizing on Scientific Progress: 
Investment in HIV Prevention R&D in 2010,6 
a report by the HIV Vaccines & Microbicides 
Resource Tracking Group, the total global 
investment—including commercial, public 
and philanthropic support—in research and 
development reached $1.9 billion for four key 
prevention options: preventive HIV vaccines, 
microbicides, oral pre-exposure prophylaxis (PrEP) 
using ARVs and operations research related to 
male circumcision.
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HIV/AIDS-related private philanthropy continues to represent only a small part of the resources available to HIV/AIDS 
in comparison to funding from government sources.
About half of all resources available for the HIV/AIDS response in low- and middle-income countries is provided by 
those countries for their own epidemics; the other half is provided in the form of international assistance from donor 
governments and non-governmental philanthropic sources. The UNAIDS and Henry J. Kaiser Family Foundation 
report on funding from donor governments found that disbursements for international AIDS assistance by donor 
governments totaled $6.9 billion in 2010, a decrease from 2009 by 10%, after years of steady growth from 2002-
2008.7,8 According to the report, the decrease was due to a combination of three main factors: actual reductions in 
development assistance, currency exchange fluctuations, and a slowdown in the pace of U.S. disbursements, which 
was not a budget cut.
7  UNAIDS and the Henry J. Kaiser Family Foundation. Financing the Response to AIDS in Low- and Middle-Income Countries: International Assistance 
from Donor Governments in 2010. August 2011. Available at: www.kff.org/hivaids/upload/7347-07.pdf.
8  Funding from donor governments for international AIDS assistance was essentially flat from 2008-2009.
Chart A:  International Assistance to HIV/AIDS in Low- and Middle-income Countries from Donor Governments
Current Resources: Donor Governments & Private Philanthropy
Source:  UNAIDS and the Henry J. Kaiser Family Foundation. Financing the Response to AIDS in Low- and Middle-Income Countries: 
International Assistance from Donor Governments in 2010. August 2011. 
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It is worth noting that although they provide the most resources by far as a group, many governments only support 
specific areas or priorities. For example, the U.S. government focuses primarily on treatment, prevention and 
medical care. Advocacy—which can encompass a range of activities to change public opinion, community and 
institutional norms, government policy and outcomes9— is not a main focus area of the U.S. government’s funding, 
even though it is well known as a tool that can maximise impact.
Also, some governments choose not to provide resources targeting or supporting certain marginalised 
populations, even if such populations are disproportionately affected by HIV. Such decisions often stem from lack 
of awareness about such populations; associated social, cultural, economic and political stigma; and restrictive 
legal regimes. Governments in many countries are unwilling or unable to fund programming specifically for men 
who have sex with men (MSM), even though HIV prevalence is nearly always higher in this community than among 
the general population. One of the main challenges to efforts to change that situation is that 76 countries currently 
criminalise same-sex relations10, which obstructs the ability of these individuals to access needed HIV treatment and 
prevention interventions. 
9  As defined by Dose of Change, available at http://issuu.com/doseofchange/docs/advocacy_glossary 
10  The International Lesbian, Gay, Bisexual, Trans and Intersex Association (ILGA). State-sponsored Homophobia: A world survey of laws criminalizing 
same-sex sexual acts between consenting adults. May 2011. Available at: old.ilga.org/Statehomophobia/ILGA_State_Sponsored_Homophobia_2011.pdf
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Chart B:  International Assistance to HIV/AIDS in Low- and Middle-income Countries  
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11   WHO/Europe. HIV/AIDS Surveillance in Europe. 2009. Available at: www.euro.who.int/data/assets/pdf_file/0009/127656/e94500.pdf
12   Health Protection Agency. United Kingdom new HIV diagnoses to end of June 2011. Available at: www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1237970242135
13  Semaille C et al. “Recently acquired HIV infection in men who have sex with men (MSM) in France, 2003–2008.” Eurosurveillance. 2009.
KNOW YOUR EPIDEMIC – FINDING THE GAPS
Selected data on the global AIDS epidemic 
are provided throughout this report to 
contextualise the philanthropic response. 
Epidemics vary widely according to 
country context, which is why it is critical 
for policymakers to “know” their epidemic 
in order to achieve maximum impact. 
Experience to date indicates, however, 
that responses do not often match with 
knowledge, especially in regards to 
marginalised populations. For example:
In nearly every country in the world, prevalence 
is much higher among sex workers and men 
who have sex with men than among the general 
population—yet with few exceptions, members of 
those populations are less likely to have access to 
prevention and treatment services.
  » In Eastern Europe and Central Asia, a region 
of concentrated new infections in populations 
such as injecting drug users, sex workers, and 
men who have sex with men, only 11% of HIV 
prevention investments are focused toward these 
higher-risk populations.
  » The proportion of HIV prevention funding for 
programmes for sex workers, men who have sex 
with men, and injecting drug users was only 1.7% 
in Burkina Faso, 0.4% in Côte d’Ivoire and 0.24% 
in Ghana in 2008, yet the estimated percentage 
of new infections in 2010 in those population 
groups was 30%, 28% and 43%, respectively.
  » In both Kenya and Mozambique, an estimated 
one quarter to one third of new HIV infections 
occur among injecting drug users, men who 
have sex with men and sex workers. Yet total 
spending directed to HIV prevention among these 
key populations in 2008 was 0.35% in Kenya 
and 0.25% in Mozambique, and almost all from 
international sources.
Source: UNAIDS Report on the Global Epidemic, 2010. Available at: www.
unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf.
In Western and Central European countries, migrant 
populations and men who have sex with men are 
disproportionately affected by HIV/AIDS. In 2009, 
37% of new HIV infections in Western Europe were 
among men who have sex with men, making sex 
between men the leading mode of transmission (if 
persons who contracted HIV abroad in countries 
with generalised epidemics are excluded).11 In 
the United Kingdom, for example, sex between 
men represented 41% of new HIV diagnoses by 
transmission category in 2010, and Africans in 
the United Kingdom accounted for 31% of new 
diagnoses among ethnic groups in 2010.12 In 
France, men who have sex with men account for 
over half of new HIV infections in men, yet they 
represent less than 2% of the country’s population.13
Source:  UNAIDS Report on the Global Epidemic, 2010. Available at: www.unaids.org/globalreport/documents/20101123_
GlobalReport_full_en.pdf.
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Chart C: Median Coverage of HIV Prevention Programmes for Selected Population Groups, 2010
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14   UN General Assembly. Political Declaration on HIV/AIDS: Intensifying our Efforts to Eliminate HIV/AIDS. A/RES/65/277. June 2011.  
Available at: www.un.org/ga/search/view_doc.asp?symbol=A/65/L.77
15   Global Fund to Fight AIDS, Tuberculosis and Malaria. Making a difference: Global Fund Results Report 2011.  
Available at: www.theglobalfund.org/documents/publications/progress_reports/Publication_2011Results_Report_en/.
16   Schwartländer et al. “Towards an improved investment approach for an effective response to HIV/AIDS.” The Lancet. 3 June 2011, 2031–41. 
At the UN General Assembly High Level Meeting on AIDS in June 2011, commitments were made to achieve new 
targets by 2015, such as eliminating vertical transmission, halving sexual transmission of HIV, and getting 15 million 
people on treatment. Commitments were also made to reach the UNAIDS estimate of what is needed to achieve 
universal access to HIV prevention, treatment, care and support by 2015 in low- and middle-income countries– 
at least $22 billion annually—and to close the $7 billion annual gap between the estimated total resources 
allocated to HIV/AIDS and what is needed.14 While philanthropy cannot be expected to fill the resource gap alone, 
philanthropic organisations and corporations can use their visibility to influence policymakers, other funders, media, 
and the public. Philanthropic organisations can also build coalitions that share resources and increase leveraging 
power. Coordinated actions across the field could serve as a catalyst that inspires new and existing donors to rally 
for increased funding and better use of funds, and could make a huge impact. 
Such a rally is imperative, as the resource gap appears likely to grow wider because, in the current economic 
climate, many donors– philanthropic, government, and others– are allocating fewer resources for HIV/AIDS. A 
notable example of the global resource challenge is that the Global Fund—the second most important source 
of international HIV/AIDS assistance after bilateral funding—is currently underfunded. During its most recent 
replenishment drive, donor governments from 40 countries pledged a total of $11.7 billion for the years 2011-2013. 
That amount was about $1.3 billion less than what the Global Fund itself considered minimal to meet its current 
commitments and continue to make grants to countries in need moving forward.15
Few stakeholders or observers dispute the argument that HIV/AIDS can only be fully addressed with more resources. 
A growing number are making the case, however, that spending more money now is the cost-effective approach 
over the long run. Most notably, an investment framework16 developed under UNAIDS auspices proposes 
a comprehensive, longer-term approach to the global HIV/AIDS epidemic based on three programme areas: 
basic programming (mostly treatment but also prevention tools such as prevention of vertical transmission, male 
circumcision, condom promotion, and programmes for key populations such as injecting drug users, sex workers, 
and men who have sex with men); “critical enablers” to help maximise impact of resources and programming (such 
as community mobilisation); and synergies with development sectors (such as health systems improvement and HIV 
education in schools and workplaces). 
Global Resource Gap
Chart D:  Cost in Low- and Middle-income Countries
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Source: Schwartländer et al. “Towards an improved investment approach for an effective response to HIV/AIDS.” The Lancet. 3 June 2011, 2031–41.   
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According to the framework, resources required under this comprehensive approach would peak at $22 billion in 
2015 and then decline from 2015–2020 because of gains in efficiency, decreases in new infections, and reduced 
need for services for people living with HIV/AIDS over time. The authors also conclude that adopting and sustaining 
the model to the fullest extent possible would mean an additional 7.4 million lives would be saved, 29.4 million life-
years would be gained, and 12.2 million new infections would be averted from 2011 to 2020. 
What Can HIV/AIDS Philanthropy Do?
In the changing landscape of HIV/AIDS and the global economy, the longstanding “business as usual” approach 
seems increasingly unworkable and ineffective. Amidst the overall decline in resources for HIV/AIDS in 2010, 
philanthropic HIV/AIDS funders must consider the larger context of resources needed and available for HIV/AIDS, as 
well as the evidence of what works, and develop new strategies to best take advantage of the exciting opportunities 
in prevention, treatment scale-up, advocacy and support for marginalised populations.
To maximise its effectiveness, the philanthropic sector needs to reprioritise and support strategically smarter, better 
coordinated, and more efficient interventions that target the needs of communities most impacted by the epidemic. 
Such steps are particularly important as new policies and paradigms are developed to respond to promising new 
findings, and existing tools and efforts are examined.
Resources expended towards HIV/AIDS have increased over the past 30 years in large part due to political will 
and funders’ dedicated efforts to raise the level of response, from nearly nothing 30 years ago to approximately 
$15 billion in 2010. The philanthropic sector must continue to provide a catalytic and strategic piece of the global 
response to HIV/AIDS. 
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Chart E:  Number of New HIV Infections per Year
Source: Schwartländer et al. “Towards an improved investment approach for an effective response to HIV/AIDS.” The Lancet. 3 June 2011, 2031–41.   
European Philanthropic Support to Address HIV/AIDS in 2010  |  13
In many African countries, the following common barriers 
can make accessing ARV treatment difficult for children 
and families living with HIV: shortages and poor training 
of health care workers; clinics that are few in number, 
widely dispersed or otherwise difficult for rural and other 
populations to get to; and HIV-related discrimination 
encountered in health care settings.
The Expert Patient (EP) Programme offers a solution by 
training and funding adult HIV/AIDS patients to use their 
own experience and knowledge to help other patients. 
EP initiatives support clinic tasks where feasible, thereby 
allowing doctors and nurses to focus on treating patients 
and more complex treatment work. The Programme also 
serve as an important link between healthcare settings and 
HIV-positive children and adolescents in their communities, 
providing a way for youth to access health services with 
the support of HIV-positive community members, free of 
stigma and discrimination. In addition, training 
and financial stipends 
bolster the job experience and household income of HIV-
positive people engaged in the EP initiative.
Launched in 2007, One to One Children’s Fund has 
committed to providing £110,000 (US$171,000) to fund 
48 clinics in 14 sub-Saharan African countries and to 
train 200 Expert Patients. Each EP cares for about 150 
children and adolescents, which means that more than 
30,000 children, adolescents and their communities 
are benefitting from the programme. The most recent 
evaluation (November 2010) highlights the success of the 
EP programme in streamlining services, breaking down 
barriers, empowering local people with real knowledge 
and expertise, offering better quality care to children in 
clinics and in the community, and allowing health care 
professionals to see more patients. The programme, which 
relies on EPs’ developing their skills and becoming role 
models in their community, is also highly cost-effective.
Christine Adhiambo Ochieng, 23, describes her job as an 
Expert Patient in Kenya and the doors it has opened for 
her: “I give HIV education, adherence counselling and 
HIV health talks. I encourage families to work together 
and to bring their children in for HIV testing and care. 
[Working as an Expert Patient] has empowered me 
to take steps ahead. I have completed guidance and 
counselling [training] ... to polish my counselling career. 
I am also planning to do child counselling so that I can 
attend to both infected and affected children physically 
and psychologically.” 
An HIV patient at a clinic in Kenya is similarly positive, 
recounting, “The Expert Patients made me realise that 
patients can also play a role in their own management. 
Expert Patients are the people who have given me the 
will to live.”
The Expert Patient Supervisor in a clinic in Malawi 
reports: “Expert Patients serve as positive role models. 
Children and adolescents can discuss with Expert 
Patients their experiences as people living with  
HIV/AIDS in a relatable manner and see firsthand the 
advantages of good adherence and positive living, 
personified by EPs.”
One to One Children’s Fund: Expert Patient Programme
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EXAMPLES OF INNOVATIVE FUNDING:  
TASK-SHIFTING TO HIV-POSITIVE COMMUNITY WORKERS
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EFG was able to obtain expenditure data for 31 European funders that made HIV/AIDS-related philanthropic 
expenditures in 2010. Combined, these funders supported some 3,895 HIV/AIDS-related grants or projects, 
disbursing a total of about €107 million ($153 million).17,18
EFG asked funders about their total funding commitments in 2010, in addition to their actual expenditures. 
Commitments data can be useful for helping to gauge current and future outlays. (Expenditures—also known as 
“disbursements” in some cases—are the amount of funding expended on grants/projects in a given year and may 
include funding from commitments made in prior years as well as in the current year. Commitments are funding 
committed for grants/projects in a given year, whether or not the funds were paid out in that year. For some funders, 
commitments and expenditures are the same in a given year; for others, commitments indicate funding above or 
below actual expenditures in a year.)
Table 1: European Philanthropic HIV/AIDS Funders in 2010 (ranked by amount of expenditures)
Name
Expenditures Commitments
€ $ € $ 
Wellcome Trust 33,385,564 47,911,624 10,034,165 14,400,000
Sidaction 11,413,175 16,379,047 764,924 1,097,742
Children’s Investment Fund Foundation, UK 11,379,022 16,330,000 1,334,041 1,914,482
Elton John AIDS Foundation, UK 8,882,860 12,747,793 1,219,112 1,749,548
ViiV Healthcare19 6,443,185 9,246,615 4,576,240 6,567,349
Comic Relief 6,082,214 6,895,954 75,000 107,633
STOP AIDS NOW! 4,816,000 6,911,442 5,000,000 7,175,500
Aids Fonds 4,668,000 6,699,047 3,827,000 5,492,128
FXB International (Fondation François-Xavier Bagnoud) 3,210,192 4,606,937 627,723 900,845
The Monument Trust 2,656,996 3,813,055 486,169 697,701
The Diana, Princess of Wales Memorial Fund 2,458,866 3,528,719 12,438,123 17,849,950
Deutsche AIDS-Stiftung 1,688,291 2,422,866 3,120,300 4,477,943
Fondation de France 1,619,159 2,323,655 18,594,156 26,684,473
Fundación La Caixa 1,334,041 1,914,482 12,860,434 18,456,009
Oak Foundation 1,099,827 1,578,358 298,000 427,660
Fondazione Cariplo20 1,000,000 1,435,100 122,308 175,525
GlaxoSmithKline21 875,335 1,256,193 15,335,917 17,387,709
HOPEHIV 765,275 1,098,247 604,689 867,789
St Stephen’s AIDS Trust22 733,033 1,051,975 206,847 296,845
Fondation Mérieux 604,689 867,789 209,045 300,000
King Baudouin Foundation 572,219 821,191 183,419 263,224
Egmont Trust 538,110 772,242 1,408,997 2,022,052
Cecily’s Fund 468,837 672,828 338,452 485,713
Sigrid Rausing Trust23 340,137 488,131 1,688,291 2,422,866
Mama Cash 298,000 427,660 Not available -
One to One Children’s Fund 272,415 390,942 Not available -
Aga Khan Foundation24 186,309 267,371 Not available -
AVERT 183,419 263,224 765,275 1,098,247
Barry & Martin’s Trust 129,208 185,426 Not available -
Aids & Child 117,940 169,256 Not available -
Calouste Gulbenkian Foundation 24,000 34,442 Not available -
Total for 2010 €106,901,059 $153,413,709 €96,118,628 $133,318,933
To avoid double-counting of funds, the 2010 expenditures total reflects a reduction of€ €1,345,260 ($1,930,582) to correct for re-granting of funds from one EFG-tracked funder to another.
PHILANTHROPIC HIV/AIDS EXPENDITURES IN 2010
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Note on missing data: A significant majority of European private philanthropic funding on HIV/AIDS in 2010 has 
been captured in the available data. However, EFG was unable to obtain funding data from some funders, and they 
are therefore not included in this report. Among them are the following:
  » German Foundation for World Population (DSW) made €4,645,466 in grants to HIV/AIDS in 2009
  » Anglo American made $967,229 (€673,982) in grants to HIV/AIDS in 2009
  » Esperanza Medicines Foundation made 555,669 CHF (€485,450) in grants to HIV/AIDS in 2009 
 
The UK grantmaker Crusaid, which was included in previous years’ reports, merged in 2010 with the Terrence Higgins 
Trust. The Terrence Higgins Trust is mostly funded by government sources and provides direct care and support services 
for people living with HIV/AIDS, as well as sponsoring prevention and sexual health programmes.
Several other funders that made grants towards HIV/AIDS programmes in 2009 are not included this year because 
they did not make grants to HIV/AIDS in 2010. They include the following:
  » Big Lottery Fund made £14,084,694 (€15,969,085) in grants to HIV/AIDS in 2009. That amount was the second 
largest funding amount of all funders in 2009. The lack of HIV/AIDS funding in 2010 from the Big Lottery Fund 
was due to the development of a new grants programme in 2010 and is not indicative of a decision to halt or 
substantially limit such funding. Grants toward HIV/AIDS have resumed in 2011.
  » Bernard van Leer Foundation made €1,866,675 in grants to HIV/AIDS in 2009. The Foundation has shifted away 
from specifically funding HIV/AIDS towards other areas, and requested to be removed from the report.
  » Fondazione Monte dei Paschi di Siena made €260,000 in grants to HIV/AIDS in 2009.
  » The True Colours Trust, which gave £193,400 (€219,275) in HIV/AIDS funding in 2009, and The Staples 
Trust, which gave £5,075 (€5,754) in 2009, are parts of the Sainsbury Family Charitable Trusts along with The 
Monument Trust, which is included in this year’s report. The Monument Trust is the one entity of the group of 
trusts that declares health and community care, including HIV/AIDS, as a focus area.
17  Funders reported expenditures in various currencies, including euros, U.S. dollars, British pounds, and Swiss francs. This necessitated the use of exchange 
rates; the rates used consistently throughout this report were as of 25 August 2011: 1 euro = 1.4351 U.S. dollars, 1 euro = 0.8820 pounds, and 1 euro = 
1.1446 Swiss francs.
18  Because this report focuses on capturing relatively specific data on resources provided by the private philanthropy sector only, funders completing the 
survey were asked to exclude income received from any government sources and subsequently re-granted. (Government resource flows are tracked 
elsewhere; see, for example, www.kff.org/hivaids/7347.cfm for the latest UNAIDS and Henry J. Kaiser Family Foundation resource tracking of donor 
governments to HIV/AIDS.)
19  ViiV Healthcare is a specialist HIV company established in November 2009 by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for 
people living with HIV. The company has headquarters in both the United States and the United Kingdom and the grantmaking is global in nature. As 
such, ViiV Healthcare appears in both the European and U.S. HIV/AIDS resource tracking reports. (To view the Funders Concerned About AIDS report U.S. 
Philanthropic Support to Address HIV/AIDS in 2010, see www.fcaaids.org.)
20  Fondazione Cariplo committed a three-year grant in 2009 of €3 million to an HIV/AIDS project in Malawi (Project Malawi), implemented in partnership 
with the corporation Intesa Sanpaolo. One third of that grant is counted here for 2010.
21  Figures for GlaxoSmithKline (GSK) do not include funding from ViiV Healthcare, which is reported separately. In addition, data were not available either 
in English or otherwise on the GSK website for patient group funding grants for the following countries: Austria, Belgium, Bulgaria, the Czech Republic, 
Denmark, Finland, France, Germany, Hungary, Italy, Latvia, Lithuania, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, and 
Switzerland. It is estimated that this missing data would not exceed €500,000, however, as patient groups are a relatively small grants programme for GSK.
22  The funding information for St Stephen’s AIDS Trust pertains to its 2010 fiscal year, which runs from April 2009 through March 2010. Though EFG asks 
funders for funding information from the previous calendar year (in this case, January through December 2010), the St Stephen’s AIDS Trust’s 2010 fiscal 
year financial data was the only available data at the time of publication of this report. 
23  The Sigrid Rausing Trust committed a three-year HIV/AIDS-related grant in 2008 of €375,000, a three-year grant in 2010 of €300,000, and a three-year 
grant in 2010 of €225,000. One third of each grant is counted here for 2010.
24  The Aga Khan Foundation receives some income from governments, which is re-granted. The 2010 total that appears here represents only privately 
sourced grantmaking funds (government funding has been removed). Were the government funds included, Aga Khan Foundation’s HIV/AIDS total giving 
figure for 2010 would be higher.
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For the 17 of 3325 funders for which EFG has four years of comparable expenditure data (2006-2010), total funding 
expenditures in 2010 were higher than 2006—by about €9 million ($13 million), or 15%.26 
25   Chart 1 includes data from two funders that did not make HIV/AIDS grants in 2010 (to show trending): the Big Lottery Fund and Fondazione Monte dei Paschi 
di Siena.
26   Totals for 2009, 2008 and 2007 were recalculated for the set of funders for which five years of data were available, using the same exchange rates for the 
2009, 2008 and 2007 totals as were used throughout this report. All totals data for 2006 were available in euros only, and original amounts in other currencies 
were unable to be recalculated at current exchange rates.
Chart 1:  European Philanthropic HIV/AIDS Expenditures 2006-2010  
(includes only funders for which five years of data are available)
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Chart 2:  European Philanthropic HIV/AIDS Expenditures 2009-2010  
(includes only funders for which two years of data are available) 
For the 30 of 3327 funders for which EFG has two years of comparable expenditure data (2009 and 2010), 
total 2010 funding expenditures were lower when compared with the same set of funders’ HIV/AIDS-related 
expenditures EFG was able to gather for 2009. The difference was about €7 million ($10 million)—or about  
6% of those funders’ total HIV/AIDS-related expenditures.28
This decrease is in contrast to the increase from 2008 to 2009 of €94 million to €118 million among the  
27 funders for which EFG had both 2008 and 2009 expenditure data.
27   Chart 2 includes two funders that did not make HIV/AIDS grants in 2010 (to show trending): Big Lottery Fund and Fondazione Monte dei Paschi di 
Siena.
28   Totals for 2009 were recalculated for the set of funders for which both 2009 and 2010 data were available, using the same exchange rates for the 2009 
totals as were used for the 2010 data throughout this report (exchange rate as of 25 August 2011: 1 euro = 1.4351 U.S. dollars, 1 euro = 0.8820 pounds, 
and 1 euro = 1.1446 Swiss francs).
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CONCENTRATION OF PHILANTHROPIC HIV/AIDS FUNDERS
HIV/AIDS funding by European-based funders identified by EFG is concentrated among a relatively small number 
of entities. As noted in Chart 3, funding expenditures from the top 10 European HIV/AIDS funders accounted for 
86% of all identified HIV/AIDS expenditures in 2010. 
Chart 3:  Distribution of Expenditures by European Philanthropic HIV/AIDS Funders in 201029  
(by percentage of total expenditures)
29  The amounts in Chart 3 add up to €108,246,318, not the 2010 expenditures total of €106,901,059, because re-granting funds are included.
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ARCAD-SIDA provides support to more than 5,200 
HIV-positive people—65 percent of them women—
through the Centre for Attentive Listening, Support, and 
Counselling (CESAC) in Bamako, Mali. In 2009, CESAC 
initiated a peer support group named “The room of 
secrets” where women were free to discuss sensitive 
issues around HIV. This step was taken in response to 
comments by women in individual counselling sessions 
that they were worried about not being able to share their 
HIV status with others. 
Sixty-two percent of CESAC female clients participating 
in the programme are married, with 24 percent in a 
polygamous marriage. Because they lack economic power, 
they depend on their spouse and fear abandonment if 
they disclose they are HIV-positive. Yet if women do not 
disclose their HIV status, they may find it difficult if not 
impossible to seek out prevention and treatment services. 
In addition, men’s involvement in managing their own 
health issues, as well as their families’, can be limited if 
neither they nor their partners disclose their HIV status.
Consequently, ARCAD-SIDA decided to implement a 
programme in Mali (starting first in Bamako, the capital) 
providing women with support to disclose their HIV 
status. This programme, initially created by Quebec 
University in Montréal, Canada, aims to provide tools to 
people living with HIV facing the challenge of disclosing 
HIV status in various contexts of social life. ARCAD-
SIDA recruited two groups of women living with HIV 
and organised 10 workshops per group that worked to 
adapt the Canadian programme to the Malian context. 
Outreach work with 12 different women’s groups during 
workshops confirmed the following:
  » There is a high social dependence of Malian women 
on their spouse for any decision-making on sexuality, 
family planning and access to medical care issues.
  » Prevention of vertical transmission will get better 
results if women are more empowered and able to 
take it upon themselves to make their own decision 
about medical protocol, infant feeding choices, etc.
Implementation of a two-year pilot-phase programme 
is currently in progress. Results of this pilot project will 
provide evidence to improve current strategies and 
actions on HIV testing and access to care, notably for 
prevention of vertical transmission.
Fondation de France: ARCAD-SIDA project to support HIV disclosure in Mali
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EXAMPLES OF INNOVATIVE FUNDING:  
DEVELOPING EVIDENCE-BASED STRATEGIES  
TO IMPROVE ACCESS TO CARE
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Over half of the funders profiled (16 of 31), including six of the top 10 funders, had main offices in the United 
Kingdom. Four had main offices in Switzerland, three had main offices in the Netherlands, and three were  
based in France.
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Chart 4: Distribution of European Philanthropic HIV/AIDS Funders by Home Country
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Among the 16 funders for which EFG had five years of expenditures data (2006 through 2010), a total of 10 
reported a higher level of HIV/AIDS grantmaking expenditures in 2010 than in 2006. 
Six funders reported expending less on HIV/AIDS in 2010 than 2006. It should be noted that some changes in 
funding are not indicative of larger trends of decreases in funding for some funders. Many funders make multi-year 
commitments, and expenditures of those commitments can vary greatly between years.
Table 2:  European Philanthropic HIV/AIDS Funders Reporting Higher Amounts of HIV/AIDS Expenditures in 
2010 than 2006 (ranked by the size of monetary increase between reported amounts for those years)
Name 2006 (€) 2007 (€) 2008 (€) 2009 (€) 2010 (€)
Change between 
2006 and 2010 % Change
Wellcome Trust 26,108,295 24,149,727 21,995,526 31,025,137 33,385,564 7,277,269 28%
Elton John AIDS 
Foundation, UK 5,055,190 5,172,144 7,350,443 5,182,279 8,882,860 3,827,670 76%
Sidaction 7,753,319 8,632,554 10,169,355 10,691,035 11,413,175 3,659,856 47%
The Diana, Princess of 
Wales Memorial Fund 854,291 328,033 1,382,090 2,207,836 2,458,866 1,604,575 188%
Aids Fonds 3,557,791 4,314,000 5,081,000 5,722,000 4,668,000 1,110,209 31%
King Baudouin Foundation 300,000 361,695 318,317 307,199 572,219 272,219 91%
Deutsche AIDS-Stiftung 1,581,530 1,410,342 1,736,858 987,992 1,688,291 106,761 7%
Cecily’s Fund 419,887 242,456 381,656 406,995 468,837 48,950 12%
AVERT 147,907 112,778 184,360 195,959 183,419 35,512 24%
Barry & Martin’s Trust 114,107 105,654 128,859 138,538 129,208 15,101 13%
Table 3:  European Philanthropic HIV/AIDS Funders Reporting Lower Amounts of HIV/AIDS Expenditures in 2010 
than 2006 (ranked by size of monetary decrease between reported amounts for those years)
Name 2006 (€) 2007 (€) 2008 (€) 2009 (€) 2010 (€)
Change between 
2006 and 2010 % Change
Big Lottery Fund 4,794,268 124,320 5,231,191 15,969,085 0 -4,794,268 -100%
Comic Relief UK 9,278,685 14,009,284 1,701,957 5,138,232 6,082,214 -3,196,471 -34%
Fondazione Monte dei 
Paschi di Siena 300,000 61,504 50,000 260,000 0 -300,000 -100%
HOPEHIV 1,054,750 778,035 1,056,352 694,293 765,275 -289,475 -27%
Aids & Child 241,470 487,083 360,122 74,259 117,940 -123,530 -51%
Calouste Gulbenkian 
Foundation 90,000 80,000 212,800 113,720 24,000 -66,000 -73%
CHANGES IN PHILANTHROPIC HIV/AIDS FUNDING
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Table 5:  European Philanthropic HIV/AIDS Funders Reporting Lower Amounts of HIV/AIDS Expenditures in 2010 
than 2009 (ranked by size of monetary decrease between reported amounts for those years)
Name 2009 (€) 2010 (€)
Change between 
2009 and 2010 % Change
STOP AIDS NOW! 6,010,000 4,816,000 -1,194,000 -20%
FXB International (Fondation François-Xavier Bagnoud) 3,920,823 3,210,192 -710,631 -18%
Fondation de France 2,155,540 1,619,159 -536,381 -25%
Oak Foundation 1,228,636 1,099,827 -128,809 -10%
Fundación La Caixa 1,372,833 1,334,041 -38,792 -3%
One to One Children’s Fund 299,321 272,415 -26,906 -9%
Aga Khan Foundation 211,421 186,309 -25,112 -12%
Among the 14 funders for which EFG had less than five years of expenditures data but did have data available for the 
two years of 2009 and 2010, six reported a higher level of HIV/AIDS grantmaking expenditures in 2010 than in 2009. 
Table 4:  European Philanthropic HIV/AIDS Funders Reporting Higher Amounts of HIV/AIDS Expenditures in 2010 
than 2009 (ranked by size of monetary increase between reported amounts for those years)
Name 2009 (€) 2010 (€)
Change between 
2009 and 2010 % Change
Children’s Investment Fund Foundation, UK 9,330,732 11,379,022 2,048,290 22%
The Monument Trust 1,123,974 2,656,996 1,533,022 136%
Fondation Mérieux 399,262 604,689 205,427 51%
Sigrid Rausing Trust 141,724 340,137 198,413 140%
Mama Cash 207,999 298,000 90,001 43%
Egmont Trust 468,166 538,110 69,945 15%
Among the 14 funders for which EFG had less than five years of expenditures data but did have data available 
for the two years of 2009 and 2010, seven funders reported lower HIV/AIDS expenditures in 2010 than in 2009. It 
should be noted that some changes in funding are not indicative of larger trends of decreases in funding for some 
funders. Many funders make multi-year commitments, and expenditures of those commitments can vary greatly 
between years.
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In the EFG survey on 2010 HIV/AIDS funding, EFG asked funders about their anticipated expenditure levels for 
2011. Of the HIV/AIDS funders that responded to that survey question (26 of 31), 38% indicated that they expected 
an increase in HIV/AIDS grantmaking in 2011 in comparison with 2010, including five of the top 10 funders. Nine 
of the 26 funders (35%) forecast expenditures to remain about at the same level, while four of the 26 funders (15%) 
said they expected to see a decrease in HIV/AIDS expenditures in 2011, including one of the top 10 funders. Three 
funders were unsure of likely levels in 2011.
 2011 FORECAST
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Chart 5: Forecast of 2011 European Philanthropic HIV/AIDS Expenditures (by percentage of funders)
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The People Living with HIV Stigma Index provides a tool 
that measures and detects changing trends in relation 
to stigma and discrimination as experienced by people 
living with HIV. The project website (www.stigmaindex.
org) and that of the Global Network of People living with 
HIV (www.gnpplus.net) features the results of this research. 
The index is designed to increase understanding of how 
stigma and discrimination—a key barrier to accessing 
HIV prevention, treatment and care—are experienced 
by people living with HIV, and inform programmatic and 
policy interventions at the local, regional and global level.
The methodology and research design in each country 
builds on a core commitment to ethical processes (such 
as informed consent and confidentiality), as well as rigor 
and sensitivity for each individual interview. In each of the 
country projects, the research team includes partners from 
local academic institutions and other experts who can 
advise on the research design and sampling strategy that 
is appropriate to the specific context. 
The process is just as important as the product in this 
initiative. The interviews present opportunities to learn 
and engage in awareness-raising dialogue about stigma 
and discrimination, the rights of HIV-positive people, and 
empowerment of HIV-positive people to combat stigma 
and discrimination. It is also an opportunity for networks 
of people living with HIV to build their capacity by driving 
this action-based research agenda. 
Although the project’s focus and main design is similar 
globally, the research project is implemented differently 
in each country. Specific processes are unique, drawing 
on the strengths and diversity of individual partners. 
Also, the number of people interviewed may be 
different, as well as the outreach and composition of 
responses from different groups (such as men who have 
sex with men, sex workers, injecting drug users and other 
vulnerable groups). Nevertheless, all the research will be 
consistent with the ethos of the project. 
Through implementation of the People Living with HIV 
Stigma Index, individual research teams will have the 
capacity to produce key results and findings and make 
recommendations that are evidence-driven; thereby 
enabling networks of people living with HIV to better 
engage in policy work. The data has already been 
used in some countries to inform national responses, 
programmatic interventions and policy change. 
The founding organisations of this initiative (first 
conceptualised in 2004) include the Global Network 
of People living with HIV (GNP+); the International 
Community of Women living with HIV/AIDS (ICW); 
International Planned Parenthood Federation (IPPF) and 
UNAIDS. Aids Fonds supported the implementation of  
the index in different countries in Africa and Europe.
Aids Fonds: The People Living with HIV Stigma Index
The People Living with HIV Stigma Index website: 
www.stigmaindex.org
EXAMPLES OF INNOVATIVE FUNDING:  
EVIDENCE-GATHERING, ANALYSIS AND ADVOCACY
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Eighty-one percent (all but six) of funders provided data on the geographic distribution of their 2010 funding 
expenditures. EFG gathered geographic distribution data for the six other funders from annual reports, trustee’s 
reports, and funders’ websites. 
Analysis by EFG suggests that of the estimated €107 million ($153 million) expended in 2010, about €39 
million ($57 million) was expended on HIV/AIDS efforts benefiting countries in Western and Central Europe,30 
representing 36% of all European HIV/AIDS expenditures. About €67 million ($96 million)—or 62%—was 
devoted to global HIV/AIDS efforts outside of countries in Western and Central Europe. (That amount includes 
funds provided to Western and Central Europe-based organisations for work outside of their region as well as 
funds given to U.S.-based organisations, usually for work outside of the United States and Western and Central 
Europe). The geographic distribution of the remaining €2 million ($3 million), representing 2% of expenditures, 
could not be identified.
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30   As used in this report, the term “Western and Central Europe” refers to the UNAIDS geographical category (which is used for data harmonisation 
purposes). It includes the following countries: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Liechtenstein, 
Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, the United Kingdom, and Vatican City.
GEOGRAPHIC DISTRIBUTION OF FUNDING
Chart 6:  2010 European Philanthropic HIV/AIDS Expenditures by Geographic Focus  
(by percentage of total expenditures)
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In 2010, the King Baudouin Foundation conducted an 
analysis of HIV prevention and care activities for sexual 
minorities, particularly men who have sex with men, 
in Burundi. It found that few such initiatives had been 
developed. The reason was not only that funding had 
not been available, but also because sexual minorities 
vulnerable to HIV (such as men who have sex with men) 
are marginalised in society. 
As part of an effort to address this gap, the King 
Baudouin Foundation formed a partnership with Reseau 
de Reinforcement Mutuel des Acteurs de la Première 
Ligne (REMUA), a network of organisations in Burundi 
that conducts prevention activities targeting sexual 
minorities and particularly men who have sex with men. 
REMUA undertook efforts to coordinate a network of 
organisations working with or aiming to work with men 
who have sex with men, and to identify and develop a list 
of priority actions on behalf of this population. In parallel 
to initiatives occurring at REMUA, the King Baudouin 
Foundation created a new fund to provide financial 
support for projects focusing on HIV among men who 
have sex with men and other sexual minorities.
Such projects can have objectives such as raising public 
awareness, prevention or care for those infected and 
their families, and training of professionals within aid 
organisations and health structures. Projects are required 
to favour a participatory approach and involve several 
partners working in the field.
This new fund has received an initial endowment of 
€80,000 (US$125,000) to support projects in 2011 
and 2012. Additional funds will also be sought. The 
management of the fund has been entrusted to ACORD 
Burundi, which will be responsible for the implementation 
of financing of the projects.
King Baudouin Foundation:  Support fund for small-scale HIV/AIDS projects among sexual 
minorities in Burundi
EXAMPLES OF INNOVATIVE FUNDING:  
SUPPORTING MARGINALISED POPULATIONS
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EFG identified seven funders that expended €1 million or more to HIV/AIDS issues within Western and Central 
European countries in 2010. 
Table 6:  European Philanthropic HIV/AIDS Funders Allocating €1 million or More to Western and Central 
European (WCE) Countries in 2010
Name
Funding to WCE countries
Percent of  
total giving
 € $ 
Wellcome Trust 24,766,822 35,542,866 74%
Sidaction 7,419,141 10,647,209 65%
Aids Fonds 2,996,000 4,299,560 64%
Elton John AIDS Foundation, UK 1,528,436 2,193,459 17%
Fundación La Caixa 1,334,031 1,914,468 100%
Deutsche AIDS-Stiftung 1,263,695 1,813,529 75%
The Monument Trust 1,096,035 1,572,920 41%
EFG identified 13 funders out of 31 that expended €1 million or more to support HIV/AIDS issues outside  
of Western and Central European countries in 2010. 
Table 7:  European Philanthropic HIV/AIDS Funders Allocating €1 million or More to Countries outside of Western 
and Central Europe (WCE) in 2010
Name
Funding to countries outside of WCE
Percent of  
total giving € $ 
Wellcome Trust 8,618,743 12,368,758 26%
Elton John AIDS Foundation, UK 7,354,424 10,554,334 83%
Comic Relief 6,082,214 8,728,586 100%
ViiV Healthcare 5,700,650 8,181,003 88%
STOP AIDS NOW! 4,816,000 6,911,442 100%
Sidaction 3,994,035 5,731,840 35%
FXB International (Fondation Francois-Xavier Bagnoud) 3,210,192 4,606,947 100%
The Diana, Princess of Wales Memorial Fund 2,458,866 3,528,719 100%
Aids Fonds 1,672,000 2,399,487 36%
The Monument Trust 1,581,030 2,268,936 60%
Fondation de France 1,399,069 2,007,804 86%
Oak Foundation 1,099,827 1,578,362 100%
Fondazione Cariplo 1,000,000 1,435,100 100%
GEOGRAPHIC DISTRIBUTION OF FUNDING
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Chart 7:  Global Geographical Distribution of European Philanthropic HIV/AIDS Funding in 2010  
(by percentage of total expenditures)
Global Geographical Distribution of European Philanthropic HIV/AIDS Funding in 2009  
(by percentage of total expenditures)
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In 2010, two regions31 received the majority of European philanthropic HIV/AIDS funding—Eastern and Southern 
Africa (37% of total expenditures, or €40 million) and Western and Central Europe (36% of total expenditures, or 
€39 million). The largest changes from 2009 to 2010 were in Eastern and Southern Africa, which received €8 million 
more in 2009; and South Asia and the Pacific, which received €4 million in 2010, down from €11 million in 2009. 
Western and Central Africa received 7% of total funding, or €8 million in 2010, while North America (most to the 
United States or Canada for international work outside of those countries) received 5%, or €4 million. 
The category “WCE for international” describes grants made to organisations with their main offices in Western 
and Central European countries, for work that benefits countries outside of that region (such as Africa or Asia). If 
they were able, funders provided the end recipient countries of those grants (and those countries were considered 
the recipients for the purposes of this chart). However, not all funders know where a grant to a Western or Central 
European organisation working globally will end up being expended—hence the need for this category, which 
represented 4% of funding, or €4 million, in 2010. 
East Asia and Southeast Asia received 3% of total funding (€3 million in 2010, up from €2 million in 2010), while the 
Latin America region and the Eastern Europe and Central Asia region received 1% each, or €1 million in 2010. Less 
than 1% of expenditures were directed to the North Africa and the Middle East region and the Caribbean region. 
As noted in the table below, the geographic distribution of grantmaking recipients does not reflect need, as 
measured by extent of HIV/AIDS burden. Nearly two-thirds of all people living with HIV currently live in sub-Saharan 
Africa, and that region was home to about the same share (two-thirds) of new HIV infections in 2009. However, the 
sub-Saharan Africa region was recipient of less than half of total European HIV/AIDS philanthropic funding.
31  See Appendix 1 for the list of countries in each region.
UNDERSTANDING THE EPIDEMIC – FINDING THE GAPS
Region
People living with HIV  
(end of 2009) New infections (2009)
Sub-Saharan Africa 22,500,000 1,800,000
East Asia, Southeast Asia, South Asia & the Pacific 4,927,000 356,500
North America 1,600,000 70,000
Eastern Europe & Central Asia 1,400,000 130,000
Latin America 1,400,000 92,000
Western & Central Europe 820,000 31,000
North Africa & the Middle East 480,000 75,000
Caribbean 240,000 17,000
Source:  UNAIDS. Report on the Global Epidemic, 2010. Available at: www.unaids.org/globalreport/documents/20101123_GlobalReport_
full_en.pdf.
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Sidaction currently supports the Romanian Association 
Against AIDS (ARAS) in Bucharest, which works with 
marginalised populations that are vulnerable to HIV such 
as drug users, sex workers, street children and Roma 
(members of a distinct ethnic group). 
ARAS’ activities are mainly related to prevention of 
HIV through condom promotion and needle exchange 
programmes. The organisation also provides social 
assistance through self-help support groups, support for 
HIV-positive youth, distribution of hygiene products and 
help with administrative formalities. 
Three years ago, with the support of Sidaction, the 
association opened Romania’s first methadone clinic. 
Known as ARENA, it offers a comprehensive range of 
opioid substitution treatment services, including medical, 
psychological and social assistance, to more than 500 
regular users. ARAS also created a Helpline available to 
the general public with information and advice on HIV  
and sexually transmitted diseases.
In France, a paradigm shift in screening has been ordered 
by the government body Hauté Autorité de Santé (French 
National Authority for Health). The recommendation is 
based on two underlying principles: i) all people who 
are potentially sexually active and who have access to 
public health services should be systematically offered 
HIV screening, and ii) increased efforts should be made to 
screen members of populations at heightened risk. 
In this context, the organisation Le Kiosque Infos Sida 
et Toxicomanie (AIDS and Addiction Info-Kiosk) in Paris, 
supported by Sidaction, set up a community testing centre 
called a “checkpoint” in 2010 that uses rapid tests for HIV 
screening. The kiosk targets men who have sex with men 
in the central Marais district in Paris, traditionally an area 
with a strong gay community. It advertises its services in 
gay media and gay bars, saunas, and sex clubs.
A community medical centre in Paris, also supported by 
Sidaction, performed over 2,000 HIV tests during its first 
year of operation, of whom more than 3 percent found 
to be HIV-positive. The project is well-integrated into the 
health care system as the medical team maintains close 
relations with the adjacent health facilities.
Sidaction: Romanian Association Against AIDS (ARAS)
Sidaction: Le Kiosque Infos Sida et Toxicomanie (AIDS and Addiction Info-Kiosk)
EXAMPLES OF INNOVATIVE FUNDING:  
SUPPORTING MARGINALISED POPULATIONS
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Kiosque in the central Marais district of Paris offers information and testing for gay men in the community. [©Anne Guérin/Kiosque Infos Sida e  T xi omanie]
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Chart 8: Top 20 Countries by Expenditure of European Philanthropic HIV/AIDS Funding in 2010
Chart 8 shows the top 20 countries in which European philanthropies supported HIV/AIDS projects in 2010 as 
well as the total amounts provided per country. The majority of the 20 countries are either in Western and Central 
Europe or Eastern and Southern Africa. However, organisations providing services or conducting other HIV/AIDS-
related activities in the United Kingdom received the most funding by far, more than double that of recipients in the 
next highest country (South Africa). 
It should be noted that funds for scientific research are included in the totals associated with Charts 7 and 8, and 
that conclusions and outcomes from such research may eventually benefit wider populations. For example, funding 
to the United States was mostly for scientific research or for organisations working outside of the country, not 
specifically for affected populations inside the United States.
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Twenty-five funders of 31 provided survey data on the intended use of their HIV/AIDS grants and projects in 2010. 
EFG was able to gather intended use data in 2010 for five additional funders from annual reports and funders’ 
websites, but could not obtain intended use data for one funder. Chart 9 shows data for three consecutive years (2008 
through 2010) to highlight recent trends and priorities.
The “other” category includes funds from organisations that did not disaggregate data based on intended use, 
funding that was unspecified, funding that fell under multiple categories, or funding for projects that did not fall 
under pre-determined categories. Funders reported “other” uses such as: a global approach to care of orphans and 
vulnerable children, HIV prevention, related social services, and advocacy; health systems strengthening; a health 
insurance fund in Africa; and scholarships for conference attendees. 
In comparison with 2009, funding for research and prevention stayed nearly the same in 2010, while funding for 
treatment experienced the largest decrease in 2010 (about €10 million). Funding for social services, advocacy, and 
programme administration increased slightly from 2009 to 2010, while funding for orphans and vulnerable children 
and human resources decreased slightly from 2009 to 2010.
INTENDED USE OF PHILANTHROPIC HIV/AIDS FUNDING 
For more in-depth information about 2010 research investments, see Capitalizing on Scientific Progress: 
Investment in HIV Prevention R&D in 2010 by the HIV Vaccines & Microbicides Resource Tracking Group of 
AVAC: Global Advocacy for HIV Prevention, the International AIDS Vaccine Initiative (IAVI), the International 
Partnership for Microbicides (IPM) and UNAIDS. It is available online at www.hivresourcetracking.org.
Chart 9: Intended Use of European Philanthropic HIV/AIDS Funding in 2008, 2009 and 2010
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A key barrier for millions of people in rural areas of the 
world is transportation to access healthcare services. In 
many African countries, people living in rural areas must 
walk very long distances, or else pay for some form of 
transport, to reach health clinics. The long walks when 
one is sick or pregnant, or expensive taxis when one’s 
income is compromised by HIV and poverty, can make 
access physically and financially crippling. It is particularly 
hard on those living with HIV who need frequent 
healthcare services such as regular ARV drugs, check-ups, 
treatment for opportunistic infections and tuberculosis, 
and prevention of vertical transmission services. 
In addition, the compounded problems of rough terrain 
and dirt roads, healthcare worker shortages, lack of 
strong healthcare infrastructure (such as an ambulance 
service), and lack of proper vehicle maintenance and 
repair expertise can mean healthcare workers also 
face very long walks, bicycle rides, drives, or otherwise 
problematic and time-consuming attempts to reach 
people. As a result, people in rural areas cannot be easily 
reached and can die simply due to lack of transport.
Riders for Health, an organisation now working in 
several sub-Saharan African countries, recognised this 
problem and proposed a simple solution: the motorbike. 
Motorbikes are more affordable than larger vehicles to buy 
and maintain, are more rugged and are designed to ride 
on rough terrain. In addition, Riders for Health provide the 
training and maintenance infrastructure to ensure that the 
transport fleet continues to work predictably, reliably and 
cost-effectively throughout their working lives. 
To date, Elton John AIDS Foundation (EJAF) has 
purchased 120 motorbikes to be used by doctors, 
nurses and community health workers in the highlands of 
Lesotho, an extremely mountainous part of the country not 
accessible by any other type of vehicle. The motorbikes 
have brought healthcare to local communities in a much 
more cost-effective and more reliable way than building 
additional clinics. Home-based care for TB patients, which 
requires a consistent drug regimen and regular check-
ins, has also become feasible with the use of reliable 
transport - stopping the spread of drug-resistant TB to 
HIV/AIDS patients and the wider community. Antiretroviral 
treatments can also be regularly and reliably delivered 
and health education, condoms and other preventive 
measures can be easily accessed by communities.
The Riders for Health programme is an ongoing success 
and EJAF have been proud to support it. All costs 
associated with the programme are now borne by the 
Ministry of Health of the Kingdom of Lesotho with 
additional funding for specific elements from the Global 
Fund. For more information on Riders for Health please 
visit their website at: www.riders.org
Elton John AIDS Foundation, UK: Riders for Health, Lesotho
EXAMPLES OF INNOVATIVE FUNDING:  
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EFG was able to obtain information from all funders profiled on the three population groups that receive the 
greatest benefit from their funding. (Some funders reported more than three populations as their main focus, but 
they were asked to list only the top three target populations of their funding.) Chart 10 shows the percentage of  
the 31 total funders that chose each category. The categories are not mutually exclusive.
TARGET POPULATIONS FOR FUNDING
The “medical research” category was added to the list of target populations on the 2010 survey for the first time 
with the request the respondents who select it provide further detail on what, if any, populations the research targets. 
Funders that supported medical research for HIV/AIDS reported the following target populations: women, children 
and babies; and people living with HIV.
The “other” category includes populations that did not fit elsewhere. For example, funders reported people in need  
of palliative care and Ministries of Health as “other”.
Chart 10:  Target Populations for European Philanthropic HIV/AIDS Funding in 2010  
(by percentage of funders that chose each category)
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UNDERSTANDING THE EPIDEMIC – FINDING THE GAPS
It should be noted that no funders chose injecting drug users as a top target population in 2010, even 
though HIV prevalence is increasing faster in Eastern Europe and Central Asia than any other region and the 
epidemics in most of those countries remain largely concentrated among injecting drug users.
Similarly, reported target populations do not correspond to HIV prevalence and risk among other marginalised 
populations. In nearly every country in the world, for example, prevalence is much higher among sex workers and men 
who have sex with men than among the general population—yet with few exceptions, members of those populations 
are less likely to have access to prevention and treatment services.
Source:  UNAIDS Report on the Global Epidemic, 2010. Available at: www.unaids.org/globalreport/documents/20101123_
GlobalReport_full_en.pdf.
Chart C: Median Coverage of HIV Prevention Programmes for Selected Population Groups, 2010
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of private and public funding sources, often acting 
as intermediaries on the ground in a region for other 
larger funders to work with.
SOURCES OF PHILANTHROPIC HIV/AIDS  
FUNDING DATA
For this report, EFG included data for 31 HIV/AIDS-
funding philanthropic organisations based in nine 
countries in Western and Central Europe. Data were 
collected using four sources: 1) a survey tool developed 
and administered by EFG to funders, 2) email and 
telephone correspondence with funders, 3) 2010 
annual and trustee’s reports found on funders’ websites 
or sent to EFG by the funders, and 4) grants lists and 
other information provided on funders’ websites. 
EFG funder survey 
EFG distributed a survey instrument that asked 
respondents to describe their HIV/AIDS-related 
expenditures in 2010 (see Appendix 2). As with the 
2009 survey, the design of the survey of 2010 funding 
was similar to that used by Funders Concerned About 
AIDS (FCAA), which tracks HIV/AIDS philanthropic 
entities based in the United States. Both surveys 
use the geographical, intended use, and population 
categories determined and employed by UNAIDS in 
its resource flows work. Levels of commitments as well 
as eventual actual expenditures are sought in order to 
provide direct comparison with figures collected by 
FCAA and UNAIDS.
A survey package with a cover letter containing some 
background on the project was sent to some 100 
European funders by email starting in March 2011. That 
survey package was distributed to a pre-selected list 
of philanthropic organisations which EFG determined 
were most likely to have significant levels of 2010  
HIV/AIDS funding and/or were most likely to list 
HIV/AIDS as a priority funding issue. (Many of those 
contacted had been surveyed and/or participated in 
previous years’ resource tracking.) Several rounds of 
follow-up were conducted to secure as much data as 
possible directly from funders. 
Responses were received from 26 funders, either through 
Definition of philanthropy
This report covers HIV/AIDS funding from a variety 
of sectors of European philanthropy, including 
endowed, private, family, and operating foundations; 
public charities; corporate philanthropic programmes 
(corporate foundations, citizenship and direct giving 
programmes); philanthropies supported by lotteries; 
and fundraising NGO charities. Although specific 
organisation types vary, all funders covered in this 
report expend a substantial amount of independent 
philanthropic or charitable funding on HIV/AIDS 
projects and grants.
Private vs. public income
Some of the funders in this report receive income from 
various governments to support HIV/AIDS projects 
and grants. While such partnerships and projects are 
extremely valuable in allocating resources effectively, 
income received from governments has been excluded 
from total funding amounts noted in this publication 
because this report attempts to focus exclusively on 
private-sector philanthropy. (It is worth noting that 
government funds for HIV/AIDS projects and grants are 
tracked and reported by UNAIDS.32) 
European funders
Throughout the report, the term “European” is used to 
describe the funders profiled. The philanthropic entities 
that are featured in this year’s report are all based in 
Western and Central European countries. While there 
are likely to exist some HIV/AIDS philanthropies based 
in Eastern Europe (most notably, in Russia and Ukraine), 
EFG has not been able to obtain data this year on private 
philanthropic funding from funders in that part of Europe. 
The Working Group on Global Philanthropic Resource 
Tracking (consisting of EFG, FCAA, and UNAIDS) 
investigated the Eastern Europe region as part of the 
global HIV/AIDS resource tracking project in 2009 to 
further identify funders outside of Western and Central 
Europe and the United States. A key finding was that 
accurate and clear comparisons usually cannot be 
made because of differences in definition and practice. 
For example, many private philanthropic entities 
outside of Western and Central European countries 
and the United States operate on income from a mix 
32  See www.kff.org/hivaids/7347.cfm for the latest UNAIDS and Henry J. Kaiser Family Foundation resource tracking of donor governments to HIV/AIDS.
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Latin America
Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa 
Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, 
Nicaragua, Panama, Paraguay, Peru, Uruguay, Venezuela
Western and Central Europe
Austria, Belgium, Denmark, Finland, France, Germany, 
Greece, Iceland, Ireland, Italy, Liechtenstein, 
Luxembourg, the Netherlands, Norway, Portugal, 
Spain, Sweden, Switzerland, United Kingdom of Great 
Britain and Northern Ireland, Vatican City 
Eastern Europe and Central Asia
Armenia, Albania, Azerbaijan, Belarus, Bosnia and 
Herzegovina, Bulgaria, Croatia, Cyprus, Czech 
Republic, Estonia, Georgia, Hungary, Kazakhstan, 
Kosovo, Kyrgyzstan, Latvia, Lithuania, Macedonia, 
Malta, Moldova, Poland, Romania, Russian Federation, 
Serbia and Montenegro, Slovakia, Slovenia, Tajikistan, 
Turkey, Turkmenistan, Ukraine, Uzbekistan
West and Central Africa
Benin, Burkina Faso, Burundi, Cameroon, Cape Verde, 
Central African Republic, Chad, Congo (Brazzaville), 
Congo (DR), Côte d’Ivoire, Equatorial Guinea, Gabon, 
Gambia, Ghana, Guinea-Bissau, Guinea (Conakry), 
Liberia, Mali, Mauritania, Niger, Nigeria, Sao Tome, 
Senegal, Sierra Leone, Togo
East and Southern Africa
Angola, Botswana, Comoros, Djibouti, Eritrea, Ethiopia, 
Kenya, Lesotho, Madagascar, Malawi, Mauritius, 
Mozambique, Namibia, Rwanda, Seychelles, Somalia, 
South Africa, Swaziland, Uganda, United Republic of 
Tanzania, Zambia, Zimbabwe
North Africa and the Middle East
Afghanistan, Algeria, Bahrain, Egypt, Iran, Iraq, Israel, 
Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, 
Palestinian Territories, Qatar, Saudi Arabia, Sudan, 
Syria, Tunisia, United Arab Emirates, Yemen
South Asia and the Pacific
Australia, Bangladesh, Bhutan, Fiji, India, Maldives, 
Nepal, New Zealand, Pakistan, Papua New Guinea, 
Samoa, Sri Lanka, Timor-Leste
East Asia and South East Asia
Brunei Darussalam, Cambodia, China, Indonesia, 
Japan, Lao People’s Democratic Republic, Korea 
fully completed surveys (25) or other communications with 
EFG. Over 92% of estimated total philanthropic HIV/AIDS 
funding activity is captured by surveys returned to EFG 
or from direct communications from funders to EFG (€99 
million of €107 million total funding). 
To capture data for which EFG did not have survey 
responses, 2010 annual reports were reviewed for 
Barry & Martin’s Trust and Fondazione Cariplo. An 
annual report for the 2010 fiscal year was reviewed for 
St Stephen’s AIDS Trust, though the fiscal years did 
not correlate with the 2010 calendar year. A grants list 
available online was reviewed for The Sigrid Rausing 
Trust, GlaxoSmithKline, and ViiV Healthcare. Attempts 
were made to ensure that funders approved of the data 
obtained and published. 
ANALYSIS
Survey respondents were asked for both 2010 
expenditures and commitments figures; this was done 
because some funders make multi-year commitments 
that are expended in parts over several years. Survey 
respondents were asked to provide the number of 
grants or projects supported in 2010 and whether 
they predicted their entities’ funding would increase, 
decrease, or stay the same in 2011.
Funders were asked to specify the amount of resources 
expended by country as well as what country-specific 
resources were allocated for. The data collected were 
subsequently analyzed according to the 10 global 
regions as defined by UNAIDS. Funders were asked 
to distinguish, to the fullest extent possible, between 
1) funds going to Western and Central European 
countries for programmes benefiting those countries, 
and 2) funds going to Western and Central European 
countries for programmes benefiting HIV/AIDS efforts 
outside of those countries. 
Definitions for each region are as follows: 
Caribbean
Anguilla, Antigua and Barbuda, Aruba, Bahamas, 
Barbados, Bermuda, British Virgin Islands, Cayman 
Islands, Cuba, Dominica, Dominican Republic, French 
Guyana, Grenada, Guadeloupe, Guyana, Haiti, 
Jamaica, Martinique, Montserrat, Netherland Antilles, 
Puerto Rico, St. Kitts and Nevis, St. Lucia, St. Vincent 
and the Grenadines, Suriname, Trinidad and Tobago, 
Turks and Caicos Islands, U.S. Virgin Islands
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CURRENCIES
The baseline currency for this report is the euro. However, 
funders reported expenditures in various currencies, 
including euros, U.S. dollars, British pounds, and Swiss 
francs. This necessitated the use of exchange rates; the 
rates used consistently throughout this report were as of 
25 August 2011: 1 euro = 1.4351 U.S. dollars, 1 euro = 
0.8820 pounds, and 1 euro = 1.1446 Swiss francs.
LIMITATIONS: MISSING DATA AND  
UNDER-REPORTING 
EFG recognises that its data for 2010 HIV/AIDS 
philanthropic funding are likely to have missed  
HIV/AIDS expenditures from some institutions for which 
EFG had no information or incomplete or unverified 
data. EFG was also unable to collect data from some  
of the philanthropic organisations that did not respond 
to the survey, in addition to institutions for which annual 
reports were unavailable. 
In the case of corporations, businesses are not required 
to disclose details about corporate philanthropic 
giving, thus making measurement of corporate 
philanthropic efforts even more challenging than 
estimations of private foundation/public charity giving. 
Adding to the special nature of such calculations, 
corporations are neither required nor always able to 
place a value on the many forms of other support they 
can and do offer, such as workplace programmes, 
volunteer efforts by their employees, in-kind donations, 
cause-related marketing, and similar activities. Finally, 
philanthropic support is often not collected centrally 
within corporations and may be higher than reported  
in this publication.
The definition of HIV/AIDS-related philanthropy in 
the survey was intentionally inclusive and broad, in 
acknowledgement of the fact that such efforts often 
overlap with many other issue areas of philanthropy. 
Therefore, some respondents have excluded grants and 
projects that were not wholly focused on HIV/AIDS efforts. 
(DPR), Korea (Republic), Malaysia, Mongolia, Myanmar, 
Philippines, Singapore, Thailand, Vietnam
EFG also asked about the intended use of HIV/AIDS 
expenditures using the following nine categories: 
  » HIV/AIDS awareness and prevention (including  
harm reduction);
  » HIV/AIDS-related treatment and medical care 
(including provider and patient treatment 
information);
  » HIV/AIDS-related social services (e.g., housing, 
employment, food, legal);
  » HIV/AIDS public policy, advocacy and 
communications;
  » HIV/AIDS research (including medical, prevention, 
and social science research); 
  » orphans and vulnerable children;
  » human resources (e.g. training, recruitment and 
retention of health care workers); 
  » programme management and administration (e.g., 
core support); and
  » other
EFG also asked funders to identify the three population 
groups that benefit the most from their funding. The tally 
of responses captures the number of funders focusing on 
particular groups, not the relative share of actual funding 
dedicated to addressing these groups.
CALCULATIONS OF RE-GRANTING
To avoid counting the same funds twice, data in this 
report are adjusted to account for known re-granting. 
Re-granting refers to funds given by one EFG-tracked 
funder to another for the purposes of making  
HIV/AIDS-related grants. The 2010 aggregate total 
for all funders was adjusted downward by €1,345,260 
($1,930,582) to account for known re-granting. That 
adjustment represents about 1% of the total estimated 
2010 HIV/AIDS philanthropic expenditures. The 
re-granting figures are estimates based on direct 
communications with funders following review of EFG 
survey and annual report data. The true re-granting 
total is likely slightly higher than the total used for 
calculating the 2010 total. 
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such, quantifying the monetary value of specific HIV/AIDS  
services for a corporation with facilities in several 
countries is very difficult and is usually not available.
In addition, other forms of support—such as volunteer 
efforts by corporate employees, matching donations 
programmes, in-kind donations, cause-related 
marketing, and donations of technical assistance—are 
not always able to be valued monetarily or tracked as 
such. They are nonetheless valuable resources offered 
by corporations, especially those that can leverage 
other investments or build the capacity of communities 
to operate their own programmes and services.
The following is a list of corporations with their 
main offices in Europe that were not covered by this 
report but are known to support HIV/AIDS workplace 
programmes or other HIV/AIDS activities. Many of 
these corporations provide information about their  
HIV/AIDS programmes on their websites.
Accor
www.accor.com
Air France KLM
http://corporate.airfrance.com
AREVA Group
www.areva.com
Axios
www.axios-group.com
Bavarian Nordic
www.bavarian-nordic.com
Bayer AG
www.bayer.com/en/Social-Initiatives.aspx
bioMérieux
www.biomerieux.com
Bionor Immuno
www.bionorimmuno.com
BMW Group
www.bmwgroup.com
Boehringer Ingelheim
www.boehringer-ingelheim.com
Bosch
www.bosch.com
BP
www.bp.com
Other Types of  
HIV/AIDS Support 
The data in this report represent financial contributions 
only from HIV/AIDS funders, in the form of external 
grants and programmes. Such financial contributions 
can be used to conduct a trend analysis because 
they are quantifiable as monetary amounts and are 
measurable in a clear and distinct way. However, many 
funders contribute in other important ways that are not 
as easily quantifiable or measurable. Some examples 
are noted below.
PRIVATE OPERATING FOUNDATIONS
Private operating foundations are those that use the 
bulk of their resources to run their own charitable 
programmes and make few, if any, grants to 
outside organisations. In some cases, the HIV/AIDS 
philanthropy reported to EFG includes the value of 
programmatic efforts and operational grantmaking, but 
not operational (internal) staff or other costs.
FUNDERS WITH A BROADER FOCUS
In some cases, funders choose to support projects 
across broad focus areas, such as health systems 
strengthening or sexual and reproductive health, where 
funding for HIV/AIDS would only be a part of a grant or 
project. EFG asks funders to report a project or grant if 
a significant aspect is focused on HIV/AIDS; however, 
some funders may not be able to separately quantify 
specific HIV/AIDS funding. Of course, all HIV/AIDS 
interventions are important and should be encouraged, 
including the more broad approaches, even though 
they are difficult to track.
CORPORATE PROGRAMMES
Several corporations that operate HIV/AIDS 
programmes are not willing or able to report those 
programmes financially. In some cases, corporations do 
not centrally or specifically track HIV/AIDS expenditures 
and therefore reporting is not feasible. Also, many 
corporations with branch facilities in areas highly 
affected by HIV (such as in sub-Saharan Africa) support 
workplace programmes that provide HIV/AIDS services 
to employees, sometimes extending those services to 
employees’ families or all community members. Those 
HIV/AIDS-specific services are usually offered with other 
health services at a corporate facility’s on-site clinic. As 
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OTHER SOURCES OF SUPPORT
Research institutions, hospitals, clinics, 
counselling centres, churches, homeless 
shelters, orphanages, community health 
programmes, private individual donors, 
and anonymous donors all represent 
other sources of HIV/AIDS funding, 
goods, and services that are difficult to 
identify and/or quantify. Even so, their 
contributions are highly valuable.
Rio Tinto
www.riotinto.com
SABMiller
www.sabmiller.com
Sanofi Aventis
www.sanofi-aventis.com
Shell
www.shell.com
Siemens AG
www.siemens.com
Solvay
www.solvay.com
Standard Chartered Bank
www.standardchartered.com
StatoilHydro
www.statoilhydro.com
Total
www.total.com/en/home_page
TV5Monde
www.tv5.org
Unilever Global
www.unilever.com
Veolia Environnement
www.veolia.com
Vestergaard Frandsen Inc.
www.vestergaard-frandsen.com
Virgin Group 
www.virginunite.com
Xstrata plc
www.xstrata.com
British American Tobacco
www.bat.com
Consolidated Contractors Company
www.ccc.gr
Crucell
www.crucell.com
Daimler AG
www.daimler.com
Diageo 
www.diageo.com
Eni
www.eni.it
Esteve
www.esteve.es
F. Hoffman-La Roche Ltd
www.roche.com
FIT Biotech
www.fitbiotech.com
GDF Suez
www.suez.com
Generation Investment 
Management LLP
www.generationim.com
Heineken N.V.
www.heinekeninternational.com
HSBC
www.hsbc.com
Imperial Tobacco Group
www.imperial-tobacco.com
L’Oréal
www.loreal.com
Lafarge
www.lafarge.com
Publicis Groupe
www.publicis.com
Novartis Foundation for 
Sustainable Development
www.novartisfoundation.org
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Return your completed survey:  
      rt@hivaidsfunders.org 
      +1-617-674-2240
Questions: 
 rt@hivaidsfunders.org  
 +1-781-899-1936
HIV/AIDS Philanthropy Survey on 2010 Funding
Please comPlete this survey by April 18, 2011 
Name of Organisation: _______________________________________  Name of Contact: _________________________________________
E-mail Address: _____________________________________________  Telephone: _______________________________________________
postal address where you would like the final report to be sent:  _______________________________________________________
Disbursements: most of the survey is based on data for grant and 
project disbursements. Please count the total value of all grants/
projects that were paid out in calendar year 2010. Disbursements 
are the amount of funding expended on grants/projects in a given 
year and may include funding from commitments made in prior years 
as well as in the current year. 
Commitments: commitments are funding pledged for grants/
projects in a given year, whether or not the funds were 
disbursed in that year. 
Defining an HiV/AiDS grant or project: in addition to reporting 
on grants/projects that are focused explicitly on hiv/aiDs, please 
include grants/projects made in other health, social, economic, and 
political areas when a significant aspect of the grant or project 
included a focus on hiv/aiDs.
Activities to include: Please restrict your answers to external 
hiv/aiDs grantmaking/projects (i.e. Do not include internal 
disbursements on staff and/or other programming).
Do not include grants/projects disbursed or committed from 
funding received from any government.
Do not include the value of donated services, products, or other 
in-kind donations (please report in question 8a). 
Foundations that operate their own programmes should report 
direct HiV/AiDS programme disbursements only and should 
not include staff costs. 
In answering the following questions, please note:
QUESTIONS FOR CALENDAR YEAR 2010
2a.  What was the total amount of your HIV/AIDS grant/project 
disbursements (funding paid out) in 2010?  
 
2b.  What was the total amount of your HIV/AIDS grant/project 
commitments (funding pledged) in 2010? 
2c.   how many hiv/aiDs grants/projects were supported  
by your organisation in 2010?  
 increase  remain the same   unsure
 decrease  discontinue  yes  No
3a.  compared to 2010, please predict whether the total amount of 
your hiv/aiDs disbursements in 2011 will: (select only one)
3b.  if your hiv/aiDs funding will likely decrease or discontinue 
in 2011, is that a result of disbursing more funding towards 
other related areas (such as health systems strengthening, or 
maternal and child health)?
All subsequent questions refer to grant/project disbursements only.
Additional Notes:
1.    Please note what currency is used for monetary amounts reported in the survey: 
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 4a.  in 2010, where were your HiV/AiDS grant/project  
funds disbursed? 
Please approximate total amounts as best you can for your grant 
recipients/ projects by country. The country would be where 
the recipient’s main office is situated. Grants to intermediary 
recipients (who then give the funds to end recipients) should be 
reported by the country where their main office is located. Funding 
provided directly to the Global Fund, WHO, UNAIDS, and other 
multilateral organisations should be entered into the appropriate area 
below and not the countries where they are located.  
Note: The amounts reported here should add up to your total 
amount of disbursements reported for question 2a.
4b.  Please provide the total amount disbursed to grantees/projects 
with main offices located in Western and Central Europe* 
or the united states for hiv/aiDs work that benefits 
projects outside of these regions (such as sub-saharan 
africa, asia, eastern europe or latin america): 
4c.  if possible, please provide the end recipient countries and 
amount of funding from question 4b:  
GEOGrApHiC DiSTribuTiON
5.  in 2010, what was the intended use of your grants/projects?  
Please approximate total amounts as best you can for the intended 
use of your grants/projects.
   hiv/aiDs awareness and prevention 
(including Pmtct and harm reduction)
   hiv/aiDs treatment and medical care 
(including provider and patient treatment 
information and home-based care) 
   hiv/aiDs-related social services (e.g. 
housing, employment, food, legal)
   hiv/aiDs public policy, advocacy, and 
communications (e.g. human rights 
programmes)
   hiv/aiDs research (including medical, 
prevention, and social science research)
   orphans and vulnerable children
   hiv/aiDs human resources (e.g. training, 
recruitment, and retention of health care workers)
   Programme management and administration (e.g. 
core support, m&e, facilities investment)
   other (e.g. health systems strengthening, 
or related mDG areas such as maternal and 
child health) Please specify:  
 _________________________________
Note: The amounts reported here should add up to your total 
amount of disbursements reported for question 2a
6.  Target populations: check the three population groups that 
received the greatest benefit from your hiv/aiDs funding in 
2010. the categories below are not mutually exclusive. Please 
mark the three that best reflect the main target populations 
reached through your funding in 2010. 
 
Please only pick three 
  People living with hiv/aiDs
  Women
  youth
  orphaned/vulnerable children
  migrants
  refugees
  injecting drug users
  sex workers
  health care workers
  men who have sex with men
  homeless/impoverished persons
  rural populations
  incarcerated people
  medical research projects that support the following 
population(s): _______________________
  other: (_______________________)
iNTENDED uSE & TArGET pOpulATiONS
Countries of grant recipients Amount by country
the Global Fund
Who, uNaiDs, other multilaterals
Additional Notes:
* the uNaiDs definition of Western and Central Europe (which we use for 
data harmonisation purposes) consists of the following countries:  
austria, belgium, Denmark, Finland, France, Germany, Greece, iceland, ireland, 
italy, liechtenstein, luxembourg, Netherlands, Norway, Portugal, spain, sweden, 
switzerland, Kingdom of Great britain and Northern ireland, and vatican city
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7a.  re-granting: if you received $50,000 or more from any 
other philanthropic organisation in 2010, please list grantor 
and the value of grant received from each foundation that 
were subsequently re-granted through your organisation for 
hiv/aiDs programmes. Note that your organisation’s total 
grantmaking, including funds you re-granted, will be reflected 
in the eFG report.* 
Grant received from Total re-granted to  
other organisations
7b.  in 2010, did you receive any income from any governments?*
8a.  in-kind donations: Please list examples of any hiv/aiDs-
related in-kind donations you made in 2010. 
8b.  Did you provide any technical assistance* in 2010? Please 
provide the financial value or please describe.  
* technical assistance is the transfer of expert knowledge, such as professional 
advice and training, from a grantmaker to a grantee.
•  highly efficient programme
•  lesson learned
•  highly effective programme
•  evidence-based intervention
•  long-term/sustainable programme
HElpiNG uS HElp yOu
 yes  No
thank you for participating in the 2011 eFG resource 
tracking survey. European Philanthropic Support to Address 
HIV/AIDS is the most accurate and thorough guide to hiv/
aiDs-related private giving in europe, and is sought after 
by foundations, policy makers and media alike. this critical 
data – developed with the participation and commitment of 
funders like you – serves as the preeminent tool to mobilise 
the philanthropic sector’s response to hiv and aiDs. a 
summary of your response, and that of your colleagues, will 
be published in the next edition of this report in November 
2011. in the interim, for more information on resource 
tracking, please visit: www.hivaidsfunders.org
ADDiTiONAl NOTES
* the purpose of this question is to avoid double-counting of funds between 
funders we track: we will subtract the amount of funds reported as re-granted 
from the “all funders” total for 2010 to avoid counting money two funders 
are reporting twice.  For example, in 2009, the total hiv/aiDs philanthropic 
expenditure was €120 million, which reflected a reduction of €2.5 million that 
was reported as re-granted from one eFG-tracked funder to another.
* eFG’s hiv/aiDs resource tracking report focuses on capturing resources 
provided by the private philanthropy sector only, and income received from any 
government is not included. (Government resource flows are tracked elsewhere; 
see, for example, www.kff.org/hivaids/7347.cfm for the latest uNaiDs and Kaiser 
Family Foundation resource tracking of donor governments to hiv/aiDs.) if you 
have received government income in 2010 but also have a significant amount of 
non-government income, please check ‘yes’ in question 7b and we will follow up 
with you and discuss how to fill out the survey.
9.  Sharing best practices: Funders have given us feedback that they particularly like learning about grants/projects their fellow funders 
are supporting. Please offer an example of an exemplary grant/project to be shared in the report, such as a:
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Egmont Trust
United Kingdom
www.egmonttrust.org
Elton John AIDS Foundation UK
United Kingdom
www.ejaf.com
Fondation de France
France
www.fondationdefrance.org
Fondation Mérieux
France
www.fondation-merieux.org
Fondazione Cariplo
Italy
www.fondazionecariplo.it
Fundación La Caixa
Spain
obrasocial.lacaixa.es
FXB International (Association 
Francois-Xavier Bagnoud)
Switzerland
www.fxb.org
GlaxoSmithKline
United Kingdom
www.gsk.com
HOPEHIV
United Kingdom
www.hopehiv.org
King Baudouin Foundation
Belgium
www.kbs-frb.be
Mama Cash
Netherlands
www.mamacash.org
Aga Khan Foundation
Switzerland
www.akdn.org/akf.asp
Aids & Child
Switzerland
www.aidsandchild.ch
Aids Fonds
Netherlands
www.aidsfonds.nl
AVERT
United Kingdom
www.avert.org
Barry & Martin’s Trust
United Kingdom
www.barryandmartin.org
Calouste Gulbenkian Foundation
Portugal
www.gulbenkian.pt
Cecily’s Fund
United Kingdom
www.cecilysfund.org
Children’s Investment Fund 
Foundation, UK
United Kingdom
www.ciff.org
Comic Relief UK
United Kingdom
www.comicrelief.com
Deutsche AIDS-Stiftung
Germany
www.aids-stiftung.de
The Diana, Princess of Wales 
Memorial Fund
United Kingdom
www.theworkcontinues.org
The Monument Trust
United Kingdom
www.sfct.org.uk/monument.html
Oak Foundation
Switzerland
www.oakfnd.org
One to One Children’s Fund
United Kingdom
www.one2onekids.org
Sidaction
France
www.sidaction.org
Sigrid Rausing Trust
United Kingdom
www.sigrid-rausing-trust.org
STOP AIDS NOW!
Netherlands
www.stopaidsnow.org
St Stephen’s AIDS Trust
United Kingdom
www.ssat.org.uk
ViiV Healthcare
United Kingdom and United States
www.viivhealthcare.com
Wellcome Trust
United Kingdom
www.wellcome.ac.uk
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